NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a research note published on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $44.00 price target on the stock.

Other analysts have also issued research reports about the company. Needham & Company LLC lowered their target price on NewAmsterdam Pharma from $42.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, May 8th. Scotiabank upped their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an “overweight” rating and a $42.00 target price for the company. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Friday, May 30th. Finally, UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $43.00.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $21.84 on Tuesday. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of -11.62 and a beta of -0.03. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29. The firm has a 50-day moving average of $17.90 and a two-hundred day moving average of $20.87.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). The firm had revenue of $2.98 million for the quarter, compared to analysts’ expectations of $1.46 million. Research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, Director James N. Topper purchased 1,135 shares of the business’s stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the purchase, the director now owns 3,013,569 shares of the company’s stock, valued at $67,775,166.81. This trade represents a 0.04% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 20.84% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc increased its stake in NewAmsterdam Pharma by 24.8% during the 4th quarter. Legal & General Group Plc now owns 22,946 shares of the company’s stock valued at $590,000 after purchasing an additional 4,556 shares in the last quarter. American Century Companies Inc. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $8,907,000. Swiss National Bank increased its stake in shares of NewAmsterdam Pharma by 105.1% in the fourth quarter. Swiss National Bank now owns 72,000 shares of the company’s stock worth $1,850,000 after acquiring an additional 36,900 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $80,000. Finally, Northern Trust Corp acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $556,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.